Hikal Limited has informed the Exchange about Investor Presentation
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited reported weak Q1FY26 results, with consolidated revenue falling 6.5% YoY to Rs. 380 Cr and EBITDA plunging 57% to Rs. 25 Cr, dragging EBITDA margin down to 6.5% from 14.3% a year ago. The company slipped into a loss with a net loss of Rs. 23 Cr versus a profit of Rs. 5 Cr in Q1FY25. Pharmaceuticals revenue dropped to Rs. 203 Cr with a negative EBIT of Rs. 26 Cr, hurt by an Official Action Indicated (OAI) status from the US FDA after a February 2025 audit, which led customers to pause offtake. Crop Protection was largely flat at Rs. 178 Cr with margins under pressure from Chinese competition. On the positive side, audits by ANVISA Brazil and PMDA Japan were cleared, the CDMO pipeline remains robust, and management reaffirmed full-year FY26 guidance, expecting recovery from Q2 onwards.
Short-term sentiment is likely negative given the sharp earnings decline and FDA overhang, though management's reaffirmed guidance and expected H2 recovery may limit downside if execution delivers. The stock may stay volatile until FDA remediation progresses and pharma offtake resumes.